218 related articles for article (PubMed ID: 20235886)
21. [
Verwer EE; Kavanagh TR; Mischler WJ; Feng Y; Takahashi K; Wang S; Shoup TM; Neelamegam R; Yang J; Guehl NJ; Ran C; Massefski W; Cui Y; El-Chemaly S; Sadow PM; Oldham WM; Kijewski MF; El Fakhri G; Normandin MD; Priolo C
Clin Cancer Res; 2018 Dec; 24(23):5925-5938. PubMed ID: 30054282
[TBL] [Abstract][Full Text] [Related]
22. Pulmonary lymphangioleiomyomatosis (LAM): progress and current challenges.
Goncharova EA; Krymskaya VP
J Cell Biochem; 2008 Feb; 103(2):369-82. PubMed ID: 17541983
[TBL] [Abstract][Full Text] [Related]
23. Lymphangioleiomyomatosis (LAM): molecular insights lead to targeted therapies.
Glasgow CG; Steagall WK; Taveira-Dasilva A; Pacheco-Rodriguez G; Cai X; El-Chemaly S; Moses M; Darling T; Moss J
Respir Med; 2010 Jul; 104 Suppl 1(Suppl 1):S45-58. PubMed ID: 20630348
[TBL] [Abstract][Full Text] [Related]
24. Lymphangioleiomyomatosis - a wolf in sheep's clothing.
Henske EP; McCormack FX
J Clin Invest; 2012 Nov; 122(11):3807-16. PubMed ID: 23114603
[TBL] [Abstract][Full Text] [Related]
25. Proapoptotic protein Bim attenuates estrogen-enhanced survival in lymphangioleiomyomatosis.
Li C; Li N; Liu X; Zhang EY; Sun Y; Masuda K; Li J; Sun J; Morrison T; Li X; Chen Y; Wang J; Karim NA; Zhang Y; Blenis J; Reginato MJ; Henske EP; Yu JJ
JCI Insight; 2016 Nov; 1(19):e86629. PubMed ID: 27882343
[TBL] [Abstract][Full Text] [Related]
26. Real-time monitoring of tumorigenesis, dissemination, & drug response in a preclinical model of lymphangioleiomyomatosis/tuberous sclerosis complex.
Liu F; Lunsford EP; Tong J; Ashitate Y; Gibbs SL; Yu J; Choi HS; Henske EP; Frangioni JV
PLoS One; 2012; 7(6):e38589. PubMed ID: 22719903
[TBL] [Abstract][Full Text] [Related]
27. Lymphangioleiomyomatosis Biomarkers Linked to Lung Metastatic Potential and Cell Stemness.
Ruiz de Garibay G; Herranz C; Llorente A; Boni J; Serra-Musach J; Mateo F; Aguilar H; Gómez-Baldó L; Petit A; Vidal A; Climent F; Hernández-Losa J; Cordero Á; González-Suárez E; Sánchez-Mut JV; Esteller M; Llatjós R; Varela M; López JI; García N; Extremera AI; Gumà A; Ortega R; Plà MJ; Fernández A; Pernas S; Falo C; Morilla I; Campos M; Gil M; Román A; Molina-Molina M; Ussetti P; Laporta R; Valenzuela C; Ancochea J; Xaubet A; Casanova Á; Pujana MA
PLoS One; 2015; 10(7):e0132546. PubMed ID: 26167915
[TBL] [Abstract][Full Text] [Related]
28. Oncogenic effects of urotensin-II in cells lacking tuberous sclerosis complex-2.
Goldberg AA; Joung KB; Mansuri A; Kang Y; Echavarria R; Nikolajev L; Sun Y; Yu JJ; Laporte SA; Schwertani A; Kristof AS
Oncotarget; 2016 Sep; 7(38):61152-61165. PubMed ID: 27458154
[TBL] [Abstract][Full Text] [Related]
29. Analysis of gene expression array in TSC2-deficient AML cells reveals IRF7 as a pivotal factor in the Rheb/mTOR pathway.
Makovski V; Jacob-Hirsch J; Gefen-Dor C; Shai B; Ehrlich M; Rechavi G; Kloog Y
Cell Death Dis; 2014 Dec; 5(12):e1557. PubMed ID: 25476905
[TBL] [Abstract][Full Text] [Related]
30. Abnormal growth of smooth muscle-like cells in lymphangioleiomyomatosis: Role for tumor suppressor TSC2.
Goncharova EA; Goncharov DA; Spaits M; Noonan DJ; Talovskaya E; Eszterhas A; Krymskaya VP
Am J Respir Cell Mol Biol; 2006 May; 34(5):561-72. PubMed ID: 16424383
[TBL] [Abstract][Full Text] [Related]
31. Immune Checkpoint Ligand PD-L1 Is Upregulated in Pulmonary Lymphangioleiomyomatosis.
Maisel K; Merrilees MJ; Atochina-Vasserman EN; Lian L; Obraztsova K; Rue R; Vasserman AN; Zuo N; Angel LF; Gow AJ; Kang I; Wight TN; Eruslanov E; Swartz MA; Krymskaya VP
Am J Respir Cell Mol Biol; 2018 Dec; 59(6):723-732. PubMed ID: 30095976
[TBL] [Abstract][Full Text] [Related]
32. Should mammalian target of rapamycin inhibitors be stopped in women with lymphangioleiomyomatosis awaiting lung transplantation?
El-Chemaly S; Goldberg HJ; Glanville AR
Expert Rev Respir Med; 2014 Dec; 8(6):657-60. PubMed ID: 25199529
[TBL] [Abstract][Full Text] [Related]
33. The next breakthrough in LAM clinical trials may be their design: challenges in design and execution of future LAM clinical trials.
El-Chemaly S; Henske EP
Expert Rev Respir Med; 2015 Apr; 9(2):195-204. PubMed ID: 25757365
[TBL] [Abstract][Full Text] [Related]
34. SRC kinase is a novel therapeutic target in lymphangioleiomyomatosis.
Tyryshkin A; Bhattacharya A; Eissa NT
Cancer Res; 2014 Apr; 74(7):1996-2005. PubMed ID: 24691995
[TBL] [Abstract][Full Text] [Related]
35. LAM cells biology and lymphangioleiomyomatosis.
Grzegorek I; Drozdz K; Podhorska-Okolow M; Szuba A; Dziegiel P
Folia Histochem Cytobiol; 2013; 51(1):1-10. PubMed ID: 23690211
[TBL] [Abstract][Full Text] [Related]
36. Faslodex inhibits estradiol-induced extracellular matrix dynamics and lung metastasis in a model of lymphangioleiomyomatosis.
Li C; Zhou X; Sun Y; Zhang E; Mancini JD; Parkhitko A; Morrison TA; Silverman EK; Henske EP; Yu JJ
Am J Respir Cell Mol Biol; 2013 Jul; 49(1):135-42. PubMed ID: 23526212
[TBL] [Abstract][Full Text] [Related]
37. Pulmonary lymphangioleiomyomatosis: A proposed state of neoplastic senescence.
Lombard CM
Med Hypotheses; 2019 Nov; 132():109372. PubMed ID: 31494502
[TBL] [Abstract][Full Text] [Related]
38. Lymphangioleiomyomatosis: New Treatment Perspectives.
Radzikowska E
Lung; 2015 Aug; 193(4):467-75. PubMed ID: 25980593
[TBL] [Abstract][Full Text] [Related]
39. Mutation analysis of the TSC1 and TSC2 genes in Japanese patients with pulmonary lymphangioleiomyomatosis.
Sato T; Seyama K; Fujii H; Maruyama H; Setoguchi Y; Iwakami S; Fukuchi Y; Hino O
J Hum Genet; 2002; 47(1):20-8. PubMed ID: 11829138
[TBL] [Abstract][Full Text] [Related]
40. Role of Prolactin Receptors in Lymphangioleiomyomatosis.
Alkharusi A; Lesma E; Ancona S; Chiaramonte E; Nyström T; Gorio A; Norstedt G
PLoS One; 2016; 11(1):e0146653. PubMed ID: 26765535
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
